PBM Bashing at the State Level
Fins to the left of me…… fins to the right….. and I’m the only PBM in town….(with apologies to Jimmy Buffet) What we are really
July 21, 2022
Fins to the left of me…… fins to the right….. and I’m the only PBM in town….(with apologies to Jimmy Buffet) What we are really
Last week we sent two reports highlighting the increasing pressure on PBMs in response to onerous business practices. The first described action being taken in
Earlier this week we issued a report on PBM business practices coming under increased scrutiny at the federal level. Well, the bullseye is not limited
PBMs continue to be under the microscope. The scrutiny comes on the heels of the FTC announcing that it was reversing its decision to shelf taking
Biosimilars are still struggling to gain maximum traction in the marketplace….. and a recent survey says that communications are at the heart of the problem.
June 28, 2022Winter Garden, FLThe FDA recently approved a new sub-cutaneous, specialty therapy, Amvuttra (vutrisiran) from Alnylam Pharmaceuticals, for the treatment of the polyneuropathy of
The word on the street is that CVS has acquired US Bioservices from AmerisourceBergen….. and it seems that CVS is treating it as a closely
The topic of the article below did not get much coverage in the media….. and that is unfortunate….. the issue should be important to all
Specialty pharmacies have, presumably, been preparing to implement new workflows to accommodate the anticipated January launch of new CMS regulations related to copay accumulator transactions.
The FDA recently approved a new form of therapy for ALS. Normally, a new form is not big news, but, for this therapy, it may
